Featured Research

from universities, journals, and other organizations

CTC screening for colorectal cancer not cost-effective when reimbursed at same rate as colonoscopy, study finds

Date:
July 27, 2010
Source:
Journal of the National Cancer Institute
Summary:
Computed tomographic colonography, also known as virtual colonoscopy, is not cost-effective if reimbursed at the same rate as colonoscopy, according to a new study.

Computed tomographic colonography, also known as virtual colonoscopy, is not cost-effective if reimbursed at the same rate as colonoscopy, according to a study published online July 27 in The Journal of the National Cancer Institute.

Colon cancer is one of the most common cancers in people over the age of 65, and there are several screening methods used to detect it. With the most commonly used procedure, colonoscopy, a small camera on a tube is inserted through the anus to remove polyps that pose a risk of colorectal cancer and biopsy lesions suspicious of cancer. Computed tomographic colonograpy (CTC) is a type of CT scan that produces three-dimensional images of the inside of the colon. If suspicious lesions are seen on the scan, the individual is referred for a follow-up colonoscopy to have those lesions removed or biopsied.

To investigate whether CTC screening every five years could be cost-effective compared to currently reimbursed colorectal screening tests, researchers used simulation models to study an unscreened cohort of Medicare beneficiaries.

Amy B. Knudsen, Ph.D., of the Institute for Technology Assessment at Massachusetts General Hospital, and colleagues, used three different simulation models to calculate the lifetime costs and life expectancy associated with 15 screening strategies, including no screening, CTC screening every five years, annual fecal occult blood test (FOBT), flexible sigmoidoscopy every five years, flexible sigmoidoscopy every five years in conjunction with the annual FOBT, and colonoscopy every ten years. They evaluated these strategies for a previously unscreened population of Medicare beneficiaries, starting at age 65.

The researchers found that "the number of life-years gained from 5-yearly CTC were only slightly lower than the number gained from 10-yearly colonoscopy screening. However, they found that if CTC was reimbursed at $488, which is approximately the same rate as colonoscopy, then lifetime costs associated with CTC screening exceed those of colonoscopy. Nevertheless, they also found that "if the availability of CTC enticed 25% of otherwise unscreened individuals to be screened, CTC would be cost-effective" at this reimbursement rate. The Centers for Medicare and Medicaid Services does not currently reimburse CTC screening, and it is unclear if more individuals would adopt colon cancer screening if offered CTC.

In conclusion, the authors write, "If CTC screening is reimbursed at roughly the same rate as colonoscopy, the cost, relative to the benefit derived and to the availability and costs of other colorectal screening tests, is too high for it to be a cost-effective screening strategy."

The researchers found that the range at which reimbursement would be cost-effective would be $108-205 per scan.

The study also "highlights that comparative effectiveness research, and cost-effectiveness analyses in particular, can also be used to inform reimbursement levels," the authors write.

In an accompanying editorial, Russell Harris, M.D, MPH, of the Cecil G. Sheps Center for Health Services Research at the University of North Carolina, raises doubts about the safety and efficacy of both CTC and colonoscopy. CTC often finds abnormailities outside the colon -- in such areas as the kidneys or adrenal glands -- that lead to further tests and procedures but likely not to longer life. Colonoscopy often leads to removal of small polyps unnecessarily, sometimes leading to complications such as bleeding, Harris writes, adding:

"Wouldn't it be interesting if we ended up, a few years from now, with neither CT colonography nor optical colonoscopy as the primary screening test but rather an improved fecal test as our 'gold standard'?"


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "CTC screening for colorectal cancer not cost-effective when reimbursed at same rate as colonoscopy, study finds." ScienceDaily. ScienceDaily, 27 July 2010. <www.sciencedaily.com/releases/2010/07/100727162856.htm>.
Journal of the National Cancer Institute. (2010, July 27). CTC screening for colorectal cancer not cost-effective when reimbursed at same rate as colonoscopy, study finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/07/100727162856.htm
Journal of the National Cancer Institute. "CTC screening for colorectal cancer not cost-effective when reimbursed at same rate as colonoscopy, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/07/100727162856.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins